Press Releases

Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Study of MDM2-p53 Inhibitor APG-115 in Combination with Immunotherapy for the Treatment of Patients with Advanced Liposarcoma or other Advanced Solid Tumors in China

SUZHOU, China and ROCKVILLE, Md., Oct. 27, 2020  — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Evaluation (CDE) of China National Medical Products Administration (NMPA) has approved a Phase Ib/II study of Ascentage Pharma’s novel MDM2-p53 Read More ›

Priority Review Granted to Ascentage Pharma’s New Drug Application for Olverembatinib (HQP1351), the First Third-Generation BCR-ABL Inhibitor in China

SUZHOU, China and ROCKVILLE, MD., Oct. 21, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Guangzhou Healthquest Pharma Co., Ltd, Read More ›

Ascentage Pharma’s Apoptosis-Targeting Drug Candidates Granted Two More Orphan Drug Designations by the US FDA

SUZHOU, China and ROCKVILLE, MD., Oct. 9, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted two Orphan Drug Designations (ODDs) to two of the company’s apoptosis-targeting assets: the MDM2-p53 inhibitor, Read More ›

Ascentage Pharma’s MDM2-p53 Inhibitor APG-115 Granted Orphan Drug Designation by the FDA for the Treatment of Gastric Cancer

SUZHOU, China and ROCKVILLE, MD., Sept. 14, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted APG-115, a novel MDM2-p53 inhibitor being developed by the company, an Read More ›

Ascentage Pharma’s Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Chronic Lymphocytic Leukemia

SUZHOU, China and ROCKVILLE, Md., Sept. 7, 2020 /PRNewswire/ — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted APG-2575, a novel Bcl-2 inhibitor being developed by the company, an Orphan Drug Designation (ODD) for Read More ›

Ascentage Pharma Releases Preclinical Results of IAP Antagonist APG-1387 in an Oral Presentations at EASL ILC 2020

SUZHOU, China and ROCKVILLE, MD., August 27, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that preclinical study results of the company’s novel inhibitor of apoptosis proteins (IAP) antagonist APG-1387 in the treatment of CHB infection Read More ›

Ascentage Pharma Releases 2020 Interim Results, Reporting the Company’s First New Drug Application and Advances in Global Strategic Collaborations

SUZHOU, China and ROCKVILLE, MD., August 18, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its interim results for the six months ended June 30, 2020. During the reporting period, Ascentage Pharma made significant strides in Read More ›

Ascentage Pharma Becomes a Constituent of Three Major Indexes Including Hang Seng Composite Index

SUZHOU, China, and ROCKVILLE, MD., August 17, 2020 —Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company has been selected as a constituent stock of the Hang Seng Composite Index (HSCI), the Hang Seng Hong Kong-Listed Read More ›

Ascentage Pharma Announces First Patient Dosed in the Phase Ib Study of MDM2-p53 Inhibitor APG-115 as Single Agent and in Combinations for the Treatment of Hematologic Malignancies in China

SUZHOU, China and ROCKVILLE, MD., July 22, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Phase Ib study of the company’s novel MDM2-p53 inhibitor candidate APG-115 as a single agent or in combinations for Read More ›

Ascentage Pharma’s Bcl-2 Inhibitor APG-2575 Granted Orphan Drug Designation by the FDA for the Treatment of Waldenström Macroglobulinemia

SUZHOU, China and ROCKVILLE, Md., July 15, 2020 — Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the US Food and Drug Administration (FDA) has granted APG-2575, a novel Bcl-2 inhibitor being developed by the company, an Orphan Drug Designation (ODD) for Read More ›